Koronis Pharma, Inc. is pioneering the development of a new class of antiviral therapeutics based on a novel mechanism – Viral Decay Acceleration™ (VDA).
Unlike other therapeutics that are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation.
Koronis' lead product candidate is KP-1461 for the treatment of HIV. In addition, the company has products in development for the treatment of hepatitis C.
There is a growing need for new antiviral therapeutics. The number of persons in the U.S. living with HIV/AIDS is increasing, and although there are more than 20 approved drugs to treat HIV infection, resistance development affects all of them and is the leading cause of treatment failure. Additionally, in the U.S., an estimated four million people are infected with hepatitis C and there are only a handful of approved drugs available.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 500 Union Street,
- Phone
- 206-682-1181
- ko****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- koronispharma.com
- Keywords
- HIV Biopharmaceutical Development.
- HQ
- Seattle, WA
Koronis Pharma Questions
Koronis Pharma's helpline number is 206-682-1181
Koronis Pharma's website is koronispharma.com
Koronis Pharma's LinkedIn profile is https://www.linkedin.com/company/koronis-pharma
Koronis Pharma has
4 employees.
View email and phone details for 4
employees at Koronis Pharma.
Koronis Pharma's industry is
Biotechnology Research
Koronis Pharma's top competitors are
Immunoscape,
Kinetic Concepts,
Excelya,
Heads,
The Match Artist,
Kraig Biocraft Laboratories, Inc.,
Winestyles Tasting Station,
Coronis Research S.a.,
Creative Pharma & Hr Services,
Polarityte.
Koronis Pharma's support email address is koronis@koronispharma.com
Koronis Pharma's categories are Biotechnology Research
Koronis Pharma's founding year is 1998
